Pacira BioSciences (NASDAQ:PCRX) Shares Gap Down Following Weak Earnings

Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) gapped down prior to trading on Friday after the company announced weaker than expected quarterly earnings. The stock had previously closed at $22.59, but opened at $21.14. Pacira BioSciences shares last traded at $21.8740, with a volume of 657,370 shares traded.

The company reported $0.57 EPS for the quarter, missing analysts’ consensus estimates of $0.85 by ($0.28). Pacira BioSciences had a return on equity of 10.16% and a net margin of 0.97%.The firm had revenue of $196.87 million during the quarter, compared to analyst estimates of $201.93 million. During the same quarter last year, the business posted $0.91 earnings per share. The firm’s revenue for the quarter was up 5.1% on a year-over-year basis.

Key Stories Impacting Pacira BioSciences

Here are the key news stories impacting Pacira BioSciences this week:

• Positive Sentiment: Record EXPAREL sales — Pacira said EXPAREL delivered its strongest fourth-quarter performance in three years, driven by 7% volume growth, signaling solid demand for its core product. GlobeNewswire Release
• Neutral Sentiment: Company provided FY-2026 revenue guidance of $745.0 million to $770.0 million (versus consensus ~$766.9M); range implies growth but sits slightly below the consensus midpoint, leaving interpretation mixed for investors. Guidance Detail
• Neutral Sentiment: Full earnings materials and call resources are available (earnings press release, slide deck and call transcripts), useful for investors wanting management commentary on margin drivers and expense cadence. Slide Deck Earnings Call Transcript
• Negative Sentiment: Earnings and revenue missed estimates — Pacira reported Q4 EPS of $0.57 vs. consensus $0.85 and revenue of $196.9M vs. $201.9M expected; the EPS shortfall and top-line miss are primary drivers of the negative price reaction. MarketBeat Earnings Summary
• Negative Sentiment: Rising expenses pressured margins — management flagged higher operating costs that reduced net income and contributed to the EPS miss, raising near-term profitability concerns. Zacks Coverage

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on PCRX shares. Needham & Company LLC restated a “buy” rating and set a $30.00 price objective on shares of Pacira BioSciences in a research note on Friday, January 9th. Truist Financial reduced their price target on shares of Pacira BioSciences from $30.00 to $28.00 and set a “buy” rating on the stock in a research report on Friday, November 7th. Wall Street Zen lowered shares of Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a report on Saturday. Weiss Ratings reiterated a “sell (d+)” rating on shares of Pacira BioSciences in a research note on Monday, December 29th. Finally, Barclays initiated coverage on Pacira BioSciences in a research note on Tuesday, December 9th. They issued an “equal weight” rating and a $27.00 target price for the company. Three equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $30.75.

Insider Activity

In other Pacira BioSciences news, SVP Lauren Riker sold 4,000 shares of the company’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $20.81, for a total value of $83,240.00. Following the completion of the transaction, the senior vice president owned 52,313 shares in the company, valued at approximately $1,088,633.53. This represents a 7.10% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Shawn Cross sold 9,104 shares of Pacira BioSciences stock in a transaction that occurred on Wednesday, December 10th. The shares were sold at an average price of $25.14, for a total value of $228,874.56. Following the sale, the chief financial officer directly owned 56,250 shares in the company, valued at approximately $1,414,125. This trade represents a 13.93% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 30,416 shares of company stock worth $744,315. 6.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Hantz Financial Services Inc. lifted its holdings in Pacira BioSciences by 175.4% in the third quarter. Hantz Financial Services Inc. now owns 1,132 shares of the company’s stock worth $29,000 after purchasing an additional 721 shares during the period. Northwestern Mutual Wealth Management Co. raised its position in shares of Pacira BioSciences by 5,900.0% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,500 shares of the company’s stock worth $39,000 after buying an additional 1,475 shares in the last quarter. Kestra Advisory Services LLC bought a new stake in shares of Pacira BioSciences during the 4th quarter worth about $48,000. Eurizon Capital SGR S.p.A. acquired a new stake in shares of Pacira BioSciences in the 4th quarter worth approximately $51,000. Finally, Global Retirement Partners LLC boosted its holdings in shares of Pacira BioSciences by 479.4% in the fourth quarter. Global Retirement Partners LLC now owns 2,028 shares of the company’s stock valued at $52,000 after acquiring an additional 1,678 shares in the last quarter. 99.73% of the stock is owned by institutional investors and hedge funds.

Pacira BioSciences Stock Down 3.0%

The company has a debt-to-equity ratio of 0.52, a current ratio of 5.26 and a quick ratio of 3.78. The firm has a market capitalization of $942.57 million, a P/E ratio of 146.07 and a beta of 0.24. The firm’s fifty day moving average price is $22.65 and its 200-day moving average price is $23.84.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.